4.2 Review

Procedure-specific pain management and outcome strategies

期刊

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.bpa.2014.03.005

关键词

post-operative pain; procedure specific; multimodal analgesia; preventive analgesia; evidence-based medicine; clinical decision support systems

资金

  1. Pfizer, New York, USA
  2. Grunenthal (Stolberg, Germany)
  3. Pfizer, NY
  4. Pacira, NJ
  5. Merck, NY
  6. CSI (Melbourne, VIC, Australia)
  7. Janssen Pharmaceuticals (Sydney, NSW, Australia)
  8. Mundipharma (Sydney, NSW, Australia)
  9. Pfizer Inc., NY
  10. Phosphagenics (Melbourne, VIC, Australia)
  11. ix Biopharma (Singapore, Singapore)

向作者/读者索取更多资源

Optimal dynamic pain relief is a prerequisite for optimizing postoperative recovery and reducing morbidity and convalescence. Procedure-specific pain management initiative aims to overcome the limitations of conventional guidelines and provide health-care professionals with practical recommendations formulated in a way that facilitates clinical decision making across all the stages of the perioperative period. The procedure-specific evidence is supplemented with data from other similar surgical procedures and clinical practices to balance benefits and risks of each analgesic technique. There is emphasis on the use of multimodal analgesia and preventive analgesia aimed at reducing central sensitization. Importantly, the benefits of dynamic pain relief may only be realized if other aspects of perioperative care such as the use of minimally invasive surgery, approaches to reduce stress responses, optimizing fluid therapy and optimizing post-operative nursing care with early mobilization and oral feeding are utilized. (C) 2014 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据